Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genzyme Tissue Repair (GZTR) -- Ignore unavailable to you. Want to Upgrade?

To: Exacctnt who wrote (1998)	7/14/1998 3:06:00 PM
From: Machaon	Read Replies (1) \| Respond to of 2553

Bob, let's hope your LGND August $12.50 calls are "in the money" by then! But, unfortunately, GENZL's giving back some today, to short term traders, IMHO. Let's hope that it rebounds before close! Earnings will be coming out a week from Wednesday. Here's some info I posted a little while ago: Any thoughts? In the 98MAR quarter, they had $2.1 million in U.S. Carticel sales, $460,000 in Europe Carticel sales, and $1.1 million in Epicel sales. If they remain on a 33% sequential, U.S. growth rate, they'll show about $2.8 million in sales this qtr. In Europe, we could possibly see about $550,000 in sales, since they said that sales were picking up. The Epicel "turnaround" process (growing skin for burn victims) was shortened significantly. A 10% sequential increase in Epicel would give us around $1.2 million in Epicel sales this qtr. I'm hoping that we can get at least $4.5 million in total sales, this qtr, or better, to show the strength and progress of their commercialization efforts. (PS: To GENZL --- A positive earnings surprise would certainly be appreciated!) Good luck, Bob